PRNewsWire
06 Nov 2026, 11:47 UTC · 57m ago
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Impact · against what's priced in
The partnership is a valuation catalyst for HIMS by removing the regulatory overhang of compounding while diversifying its revenue stream. For LLY, the news is incremental as the market already prices in the dominance and initial launch of its obesity portfolio.
- HIMS+0.50
Challenges what's priced in
- The price assumes
Significant legal and regulatory friction, including FTC lawsuits
By formally committing not to offer compounded copies of Lilly's GLP-1s, HIMS eliminates a major regulatory risk and legal friction point that the market has previously priced in.
What HIMS's price assumes · Sep 13
